Oncology Clinical Trial Protocol Template: What Sponsors, CROs, and Medical Writers Need to Know

Introduction

Ninety-one percent of oncology protocols receive at least one substantial amendment before a trial closes. That figure, drawn from a 2024 Tufts Center for the Study of Drug Development (Tufts CSDD) analysis of 950 industry protocols and 2,188 amendments ^[1], puts the scale of the problem in plain terms: the average oncology protocol is not finished when it is submitted. It is revised, sometimes repeatedly, at median direct costs of $141,000 per Phase II amendment and $535,000 per Phase III amendment ^[17] and with downstream consequences for site activation timelines, patient enrollment rates, and regulatory review.

A well-constructed protocol template designed specifically for oncology settings will not eliminate amendments entirely. Regulatory agencies make requests, science evolves, and safety data change the picture. What a disciplined template does is address the structural sources of avoidable amendments: missing biomarker plans, eligibility criteria that are either too narrow or inconsistently worded, endpoints that cannot sustain statistical review, and documentation structures that differ enough between sponsors to create regulatory friction. This article explains what a protocol template for oncology trials needs to contain, how regulatory expectations have shifted in the past two years, and where the most consequential design decisions sit.

Why Oncology Protocols Are a Different Category of Problem

The sheer structural complexity of oncology protocols sets them apart from non-oncology drug development in ways that matter for template design. Oncology clinical trial durations run 30 to 40 percent longer than trials for other drug classes, driven by more elaborate procedures and difficulty reaching narrow patient populations ^[3]. Phase II and Phase III oncology protocols generate substantially higher data volumes than non-oncology comparators, and protocol deviation rates are higher throughout ^[3].

None of this is incidental. Oncology protocols carry a longer list of required sections, more complex eligibility criteria (brain metastases status, organ dysfunction thresholds, prior therapy washout periods, biomarker positivity requirements), multiple response assessment criteria operating simultaneously (RECIST, RANO, iRECIST depending on tumor type and treatment modality), and biomarker collection plans that must align with both analytical validity requirements and regulatory acceptance standards. When any of these elements is under-specified in the initial protocol, amendments follow.

The amendment data make this visible. A Tufts CSDD 2024 study found that oncology protocols averaged 4.0 amendments each, compared to 3.0 for non-oncology protocols ^[1]. Across all phases and therapeutic areas studied, the mean number of amendments per protocol had increased 60 percent since 2015, reaching 3.3 on average, and the prevalence of protocols requiring at least one amendment had grown from 57 to 76 percent ^[2]. In oncology specifically, that prevalence reached 91.1 percent ^[1]. Regulatory agency requests and changes to study strategy ranked among the most common reasons for amending, displacing the earlier pattern of protocol design flaws and recruitment difficulties ^[2], though under-specified initial design remains a contributing factor.

A purpose-built oncology protocol template addresses the structural sources of this problem.

The ICH M11 CeSHarP Framework and What It Means for Oncology Teams

The most significant structural development in protocol documentation in recent years is the ICH M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP). The ICH M11 Technical Specification was adopted at Step 4 by the ICH Assembly on 19 November 2025 and came into effect at the EMA on 11 June 2026 ^[4]. The FDA finalized the M11 CeSHarP guidance on May 22, 2026 (Federal Register FR Doc 2026-10295), finalizing both the original 2022 draft guidance and the June 2025 revised draft technical specification ^[5]. As final FDA guidance, this document represents the agency's current thinking, though it does not establish legally enforceable requirements and alternative approaches remain permissible if they satisfy applicable statutes and regulations ^[5].

ICH M11 matters for oncology because it does two things previous templates did not do together: it standardizes the content structure of the protocol (required and optional sections, with defined cardinality) and specifies a machine-readable technical format for electronic data exchange of protocol information ^[4],[5]. For sponsors running multi-regional oncology trials, this matters practically. Protocol content that is consistently structured can be exchanged with regulatory authorities without manual reformatting, reducing the administrative burden at submission and during review.

The template applies to all interventional clinical trials regardless of therapeutic area, but the structured sections it defines map closely onto what oncology protocols already require: a risk-benefit assessment section that separates intervention risks from procedure risks, eligibility criteria presented in standardized format, an objectives and endpoints section with primary and secondary differentiation, and a biomarker-related content plan ^[4],[5]. For oncology medical writers and regulatory affairs teams, aligning an internal template to M11 now reduces future reconciliation work as regulatory authority adoption broadens.

The EMA's November 2023 sixth revision of the Guideline on the Clinical Evaluation of Anticancer Medicinal Products (EMA/CHMP/205/95 Rev. 6) added another dimension ^[6]. That revision addressed biomarker-guided development and formalized regulatory expectations around master protocol designs, including basket and umbrella trials, within the oncology protocol framework.

Core Sections of an Oncology Protocol Template

An oncology protocol template built to current regulatory expectations includes several components that deserve individual attention, because each is a common source of downstream amendments.

Objectives and Endpoints

Endpoint specification in oncology is not simply a matter of choosing between overall survival (OS) and progression-free survival (PFS). FDA draft guidance issued in August 2025 (Docket FDA-2024-D-5850, published Federal Register August 19, 2025) addresses the assessment of OS in randomized oncology clinical trials, with an emphasis on OS as a prespecified safety endpoint when it is not the primary endpoint ^[7]. The guidance recommends that when OS is not the primary endpoint, sponsors include a detailed plan in the protocol for capturing long-term survival data, that all randomized oncology trials be designed to assess OS to evaluate potential harm, and that intercurrent events such as crossover and subsequent therapies be carefully addressed in the statistical plan ^[7]. This is nonbinding guidance reflecting FDA's current thinking. Each of these elements has direct implications for the endpoints and statistical sections of the protocol template.

EMA guidance similarly holds that prolonged PFS or disease-free survival can constitute a relevant measure of patient benefit when the magnitude of effect is sufficient and adequately supported, but the bar is set against the specific tumor type and line of therapy ^[6]. Protocol templates for oncology trials should pre-populate the endpoints section with placeholders that prompt authors to specify both the primary endpoint and the evidentiary justification for selecting it, alongside the plan for collecting survival data if OS is a secondary endpoint.

Eligibility Criteria

Eligibility criteria design is one of the most consequential sections of the oncology protocol template, and it has attracted more regulatory attention in the past two years than any other single element.

On April 26, 2024, the FDA's Oncology Center of Excellence issued three draft guidance documents for industry, IRBs, and clinical investigators addressing performance status (Docket FDA-2024-D-1377), laboratory values (Docket FDA-2024-D-1402), and washout periods and concomitant medications (Docket FDA-2024-D-1376) ^[8]. These are draft, nonbinding documents reflecting the FDA's current thinking. They built on a series of earlier finalized FDA guidances covering brain metastases, HIV/hepatitis B/C infections, organ dysfunction or prior malignancies, and minimum age for pediatric inclusion ^[9]. The core recommendation across these documents is that exclusion criteria should be scientifically justified against the specific drug's mechanism of action and pharmacokinetics, not adopted by convention from earlier protocols in the same indication ^[8].

For the performance status guidance specifically, the FDA indicated that patients with ECOG performance status 2 (or Karnofsky Performance Status 60 to 70) should be included unless there is a clear scientific or clinical rationale for exclusion, and that restrictions should be reassessed as safety data accumulate ^[10]. This is nonbinding guidance; sponsors are free to use an alternative approach if it satisfies applicable requirements. The ASCO-Friends of Cancer Research collaborative, which worked with FDA and NCI on these eligibility modernization efforts, noted that the NCI revised its clinical trial protocol template to incorporate more expansive eligibility criteria for patients with brain metastases, HIV/AIDS, chronic hepatitis, and organ dysfunction as these guidances developed ^[9].

An oncology protocol template that does not include a structured eligibility criteria review mechanism (a checklist prompting the author to justify each exclusion against mechanism-of-action or pharmacokinetic data) may increase the risk of FDA or IRB queries on eligibility, and potentially amendments later.

The brain metastases question deserves separate attention. An FDA staff analysis of 297 commercial oncology IND protocols submitted in 2015 found that 77.4 percent excluded patients with known active or symptomatic brain metastases ^[11]. This reflects historical convention rather than pharmacological necessity in many cases, and FDA guidance has progressively pushed toward inclusion of this population with appropriate protocol safeguards (stratification by brain metastases status, separate response assessment criteria for CNS disease at the same timepoints as systemic assessment) ^[12].

Biomarker Plan

The EMA's sixth anticancer guideline revision placed biomarker-guided development at the center of oncology protocol design, reflecting that an increasing proportion of cancer drug applications are built around biomarker-defined populations ^[6]. A protocol template for oncology trials should include a dedicated biomarker plan section that addresses: the biomarker's analytical validity (the assay used and its acceptance criteria), clinical validity (evidence that the biomarker predicts the outcome of interest), the role of the biomarker in eligibility determination versus stratification versus exploratory analysis, and the plan for correlative sample collection and storage.

Basket and umbrella trial designs require biomarker planning at the master protocol level, with sub-study-specific refinements. EMA guidance characterizes basket trials as investigating one drug across a diverse set of tumor types sharing a response-predictive biomarker, while umbrella trials enroll a single cancer type but stratify by different molecular alterations matched to different treatment arms ^[6]. Both designs demand that the biomarker section of the protocol template handle multiple concurrent biomarker hypotheses without creating ambiguity about the primary analytical population.

Statistical Analysis Section

The statistical section is where the protocol's endpoint decisions become binding commitments, and it is also one of the most common targets for amendment. ICH E9(R1), the addendum on estimands and sensitivity analysis in clinical trials (Step 4: November 2019), applies to oncology trials and requires that the statistical analysis plan clearly define the estimand for each endpoint, including the target population, the variable, the handling of intercurrent events, and the summary measure ^[15].

For oncology templates, the statistical section should pre-specify: the primary analysis population (intent-to-treat vs. per-protocol), how biomarker-negative and biomarker-positive subgroups will be analyzed when a biomarker is central to the hypothesis, the plan for interim analyses and any adaptive design elements, and the approach to multiple testing when co-primary or hierarchical endpoints are used.

Safety Reporting and Monitoring Plan

ICH E6(R3), adopted at Step 4 on January 6, 2025, with EMA adoption on July 23, 2025 and FDA adoption in September 2025, introduced a risk-proportionate monitoring framework that applies to all interventional trials including oncology ^[13]. The monitoring section of an oncology protocol template should reflect this framework, describing the risk identification process that informed the monitoring strategy rather than defaulting to 100 percent source data verification across all sites.

For oncology-specific safety considerations, the protocol template should include placeholders for: dose modification rules (often more complex in oncology than other therapeutic areas, particularly for combination regimens), immune-mediated adverse event management guidance where checkpoint inhibitors are involved, and the adverse event grading system (CTCAE version should be specified, not left to convention).

Regulatory and Documentation Considerations

Several regulatory requirements bear directly on oncology protocol template construction.

FDA's draft guidance on multiregional clinical trials in oncology (September 2024, Docket FDA-2024-D-3163) addressed the declining proportion of US participants in cancer drug trials and established that the agency's principal concern for multi-regional oncology trials is whether results apply to the intended US use population and standard cancer care practices ^[14]. This is draft, nonbinding guidance. Protocol templates for sponsors planning multi-regional oncology trials should include a regional enrollment balance section and a plan for how US-representative data will be collected and analyzed separately where required.

The ICH M11 Technical Specification, now at Step 5 following EMA's December 11, 2025 adoption, requires that protocol content be structured to support electronic data exchange ^[4]. This is a forward-looking consideration for template design: sponsors building or updating internal protocol templates in 2025 and 2026 who do not account for M11's data exchange structure will face additional reconciliation work as authority adoption broadens. The specification defines conformance, cardinality, and term definitions for each protocol element, drawing on CDISC-managed terminology ^[4].

For EU-based or dual-jurisdiction submissions, the EU Clinical Trials Regulation (EU CTR No. 536/2014) governs the format of clinical trial information submitted through the Clinical Trials Information System (CTIS). Protocol content requirements under EU CTR and ICH M11 overlap substantially but are not identical, and an oncology protocol template intended for multi-jurisdictional use should map sections against both frameworks.

How AI and Automation Fit Into Protocol Template Development

Protocol authoring in oncology has historically involved a high degree of manual effort: pulling eligibility criteria from precedent trials, adapting statistical language from prior protocols in the same indication, checking cross-section consistency between the objectives section and the statistical plan, and verifying that biomarker collection procedures described in the laboratory section align with what the eligibility criteria require.

AI-assisted document generation can reduce the manual burden on each of these tasks, but only if the underlying template is well-structured. A system generating oncology protocol sections from sponsor-provided inputs still requires a template that enforces the right questions (eligibility justification, biomarker role specification, endpoint estimand definition) before text generation begins. The output quality of any AI-assisted protocol tool is bounded by the structural discipline of the template it operates on.

Validation requirements apply as well. FDA's October 2024 final guidance on Electronic Systems, Electronic Records, and Electronic Signatures in Clinical Investigations (Docket FDA-2017-D-1105, finalized October 2, 2024) describes the agency's current recommendations on electronic systems used to create, maintain, or transmit records in clinical investigations, including documentation of system validation ^[16]. For sponsors using AI-assisted tools to generate or manage protocol content, the potential of such a system to affect the reliability of trial results is a relevant consideration in determining appropriate validation scope ^[16]. The specific application of these principles to AI-generated protocol documents continues to evolve and should be monitored as agency thinking develops.

Human review by qualified medical writers and regulatory professionals remains necessary. Regulatory agencies evaluate protocol quality in part through the coherence of cross-section references (does the study procedures section describe assessments at timepoints consistent with the statistical analysis plan?), and automated generation does not eliminate the need for expert review of that coherence.

How Kitsa Supports Oncology Protocol Development

KScribe, Kitsa's AI-powered regulatory document generation platform, is built to support the authoring of clinical trial protocols alongside other regulatory documents including ICFs, IBs, DSURs, and CSRs. For oncology sponsors and CROs managing high-complexity protocols, the platform generates structured document sections with cross-document consistency built into the workflow, helping reduce the manual effort of ensuring that eligibility criteria stated in the protocol align with what the ICF presents to patients and what the IB describes about known safety information.

Key Takeaways

• Oncology protocols carry a 91.1 percent amendment prevalence, compared to 72.1 percent for non-oncology protocols, with an average of 4.0 amendments each; addressing the structural design sources of preventable amendments through disciplined template design may reduce avoidable amendment risk ^[1],[2].
• ICH M11 CeSHarP, adopted at Step 4 in November 2025 and effective at the EMA as of June 2026, was finalized by the FDA on May 22, 2026; it establishes a harmonized, machine-readable protocol template applicable to all interventional trials including oncology, and sponsors should align internal templates to M11 now to reduce future reconciliation work ^[4],[5].
• FDA's April 2024 draft guidances on eligibility criteria (nonbinding) recommend that exclusions be justified by mechanism of action and pharmacokinetics, not convention; this applies to performance status, laboratory values, and washout periods, building on finalized guidances for brain metastases, organ dysfunction, HIV/hepatitis, and minimum age ^[8],[9],[10].
• The EMA's sixth anticancer guideline revision (November 2023) formalized biomarker-guided development and master protocol designs (basket and umbrella trials) within the regulatory framework for oncology; protocol templates must accommodate biomarker-defined populations and multi-arm hypothesis structures ^[6].
• FDA draft guidance on OS (August 2025, nonbinding) recommends that all randomized oncology trials be designed to assess overall survival, with a prespecified plan for long-term survival data collection when OS is not the primary endpoint; this directly shapes the endpoints and statistical sections of the oncology protocol template ^[7].
• Oncology trial durations run 30 to 40 percent longer than non-oncology trials, making the initial protocol design consequential for total study costs and timelines; structural template discipline at the outset is measurably cheaper than amendments later ^[3].
• ICH E6(R3) (Step 4: January 6, 2025; EMA: July 23, 2025; FDA: September 2025) emphasizes risk-proportionate monitoring strategies; protocol monitoring plans should document the risk identification process that informed the monitoring approach rather than defaulting to conventional approaches ^[13].

FAQ

References

1. [1]Botto E, Smith Z, Getz K. "New Benchmarks on Protocol Amendment Experience in Oncology Clinical Trials." Therapeutic Innovation & Regulatory Science. 2024;58(4):645-654. https://doi.org/10.1007/s43441-024-00629-2
2. [2]Getz K, Smith Z, Botto E, Murphy E, Dauchy A. "New Benchmarks on Protocol Amendment Practices, Trends and their Impact on Clinical Trial Performance." Therapeutic Innovation & Regulatory Science. 2024;58(3):539-548. https://doi.org/10.1007/s43441-024-00622-9
3. [3]Wilkinson M, Smith Z, Getz K. "Protocol Complexity and Patient Enrollment Intensify Challenges in Oncology Trials." Tufts CSDD Impact Report. 2021;23(3). Cited in Applied Clinical Trials Online. https://www.appliedclinicaltrialsonline.com/view/protocol-complexity-and-patient-enrollment-intensify-challenges-in-oncology-trials-says-tufts
4. [4]European Medicines Agency. "ICH M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP), Technical Specification. Step 5." EMA/CHMP/ICH/778800/2022. Final adoption 11 December 2025; effective 11 June 2026. https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/ich-m11-clinical-electronic-structured-harmonised-protocol-cesharp-technical-specification-step-5_en.pdf
5. [5]U.S. Food and Drug Administration. "M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); Guidance for Industry." Final. Federal Register FR Doc 2026-10295. May 22, 2026. Docket FDA-2022-D-3054. https://www.federalregister.gov/documents/2026/05/22/2026-10295/m11-clinical-electronic-structured-harmonised-protocol-cesharp-international-council-for
6. [6]European Medicines Agency. "Guideline on the Clinical Evaluation of Anticancer Medicinal Products in Man. Revision 6." EMA/CHMP/205/95 Rev. 6. Adopted November 2023; effective 2024. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-evaluation-anticancer-medicinal-products-revision-6_en.pdf
7. [7]U.S. Food and Drug Administration. "Approaches to Assessment of Overall Survival in Oncology Clinical Trials; Draft Guidance for Industry." Federal Register Vol. 90, No. 158. August 19, 2025. Docket FDA-2024-D-5850. https://www.federalregister.gov/documents/2025/08/19/2025-15796/approaches-to-assessment-of-overall-survival-in-oncology-clinical-trials-draft-guidance-for-industry
8. [8]U.S. Food and Drug Administration, Oncology Center of Excellence. April 2024 Draft Eligibility Criteria Guidances: Performance Status (FDA-2024-D-1377); Laboratory Values (FDA-2024-D-1402); Washout Periods and Concomitant Medications (FDA-2024-D-1376). April 26, 2024. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cancer-clinical-trial-eligibility-criteria-performance-status
9. [9]Friends of Cancer Research (reporting on ASCO-Friends-NCI collaborative work). "Clinical Trial Eligibility Criteria." Updated 2024. https://friendsofcancerresearch.org/clinical-trial-eligibility-criteria/
10. [10]U.S. Food and Drug Administration. "Cancer Clinical Trial Eligibility Criteria: Performance Status. Draft Guidance for Industry, Institutional Review Boards, Clinical Investigators." April 2024. Federal Register Doc. 2024-09037. https://www.federalregister.gov/documents/2024/04/26/2024-09037/cancer-clinical-trial-eligibility-criteria-performance-status-draft-guidance-for-industry
11. [11]Jin S, Pazdur R, Sridhara R. "Re-Evaluating Eligibility Criteria for Oncology Clinical Trials: Analysis of Investigational New Drug Applications in 2015." Journal of Clinical Oncology. 2017;35(33):3745-3752. PMCID PMC5692723. https://pmc.ncbi.nlm.nih.gov/articles/PMC5692723/
12. [12]U.S. Food and Drug Administration. "Cancer Clinical Trial Eligibility Criteria: Brain Metastases. Guidance for Industry." https://www.fda.gov/media/121317/download
13. [13]International Council for Harmonisation. "ICH E6(R3) Guideline for Good Clinical Practice." Step 4 adoption: January 6, 2025. https://www.ich.org/page/efficacy-guidelines
14. [14]U.S. Food and Drug Administration. "Considerations for Generating Clinical Evidence from Oncology Multiregional Clinical Development Programs; Draft Guidance for Industry." September 2024. Docket FDA-2024-D-3163. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-generating-clinical-evidence-oncology-multiregional-clinical-development-programs
15. [15]International Council for Harmonisation. "ICH E9(R1) Addendum on Estimands and Sensitivity Analysis in Clinical Trials." Step 4: November 2019. https://www.ich.org/page/efficacy-guidelines
16. [16]U.S. Food and Drug Administration. "Electronic Systems, Electronic Records, and Electronic Signatures in Clinical Investigations: Questions and Answers." Final Guidance for Industry. October 2, 2024. Docket FDA-2017-D-1105. Federal Register FR Doc 2024-22562. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/electronic-systems-electronic-records-and-electronic-signatures-clinical-investigations-questions
17. [17]Getz KA, Stergiopoulos S, Short M, Surgeon L, Krauss R, Pretorius S, Desmond J, Dunn D. "The Impact of Protocol Amendments on Clinical Trial Performance and Cost." Therapeutic Innovation & Regulatory Science. 2016;50(4):436-441. https://doi.org/10.1177/2168479016632271